Vector innovation for improved vaccine efficacy

Development of lipid-based nanocarriers for the delivery of self-amplifying RNA as a save and durable source of protein production for therapeutic applications

VIVACE, a groundbreaking collaboration between public and private sectors, is pioneering the next chapter in vaccine development. With the rise of mRNA vaccines like Comirnaty™ and Spikevax™ during the COVID-19 crisis, VIVACE steps forward to enhance the effectiveness and accessibility.

Why It Matters:

Imagine a world where diseases are defeated before they spread, where lockdowns are a thing of the past. This is the vision driving VIVACE. Every year, millions are affected by preventable illnesses, costing economies billions. VIVACE's innovative approach seeks to change this narrative by creating vaccines that are easier to store, provide longer-lasting immunity, and offer broader protection against diseases.

How We're Changing the Game:

VIVACE's strategy is simple yet impactful. By reimagining the delivery of self-amplifying RNA, we aim to tackle the limitations faced by current mRNA vaccines. Our scientists are developing advanced nanovectors that can deliver self-amplifying RNA more effectively, ensuring that every dose reaches protection. Through high-quality research and cutting-edge technology, we're not only improving vaccine formulations but also revolutionizing the way we combat diseases.

What We Hope to Achieve:

With VIVACE our ambition is high. We aim to develop a new generation of RNA vaccines with high potency at low dose and generating long-lasting immunity.  Different nanovectors will be explored for this which will be targeted to specific subsets of immune cells. With each milestone reached, we're one step closer to realizing our vision of a healthier, more resilient world.

In conclusion, VIVACE's commitment to innovation and collaboration promises a future with better vaccines giving long-lasting protection, not only to protect against infectious diseases, but potentially also to cure debilitating diseases such as auto-immune related diseases and cancer. Together, we're unlocking the potential of vaccines and shaping a brighter tomorrow for generations to come.

Summary
During the COVID-19 pandemic, mRNA vaccines proved effective but faced limitations such as ultra-cold storage and relatively short-lived immunty. VIVACE aims to develop next-generation RNA nanovectors to overcome these limitations and create more widely applicable vaccines.
Technology Readiness Level (TRL)
1 - 3
Time period
45 months
Partners